Neostigmine, Sugammadex
Conditions
Brief summary
The study will assess the acute effects of sugammadex or neostigmine on renal function as determined with more specific and sensitive tests in laparoscopic cholecystectomy
Interventions
DRUGNeostigmine
a combination of 0.04 mg/kg neostigmine with 0.01 mg/kg atropine intravenously at the reappearance of a second twitch of TOF after the last dose of rocuronium
DRUGSugammadex
2-4 mg/kg sugammadex intravenously upon the reappearance of a post-tetanic count 1-2 or a second twitch of TOF after the last dose of rocuronium
Sponsors
Menoufia University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* normal renal function (serum Cr 0.4- 1.4 g/dL) * American Society of Anesthesiologists (ASA) Class I-II
Exclusion criteria
* Incapacity to consent. * Pre-existing impaired kidney functions. * Severe neuromuscular disease, as: myasthenia gravis & muscular dystrophy. * Intra-operative bleeding * Lengthy operations that exceed 2 hours. * Hemodynamic changes more than 20% of the base line
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| neutrophil gelatinase associated lipocalin (NGAL) values | baseline ( 2 days preoperative) and 12 hours after surgery | normal overall unisex value 47-55 ng/ml |
Countries
Egypt
Outcome results
None listed